Open access

25 Line of therapy adjustment in a patient with advanced triple-negative breast cancer (TNBC) by using personalized ctDNA test for treatment response monitoring
Georges Azzi, Shifra Krinshpun, Antony Tin, Allyson Malashevich, Meenakshi Malhotra, Paul Billings, Angel Rodriguez, Alexey Aleshin

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A13-A14; DOI: 10.1136/jitc-2020-SITC2020.0025
24 Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade
Pashtoon Kasi

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A13; DOI: 10.1136/jitc-2020-SITC2020.0024
218 A preclinical study of IMC-002, a fully human therapeutic antibody safely targeting CD47 in cancer
Hyeonseok Yoo, Jeong Kook Kim, Ji Yea Choi, Sun Kwang Song, Jihyun Park, Ara Jeon, Ji Hye Lee, Sook Kyung Chang, Yun Song

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A130; DOI: 10.1136/jitc-2020-SITC2020.0218
219 Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients
Ahmad Tarhini, David McDermott, Apoorva Ambavane, Agnes Benedict, Cho-Han Lee, Corey Ritchings, Brian Stwalley, Meredith Regan, Michael Atkins

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A130-A131; DOI: 10.1136/jitc-2020-SITC2020.0219
222 Increased PD-L1 tumor expression correlates with high rate of response to PD-1 inhibitors in patients with unresectable, recurrent, and metastatic cutaneous squamous cell carcinoma
Nate Bowers, Kimberly Burcher, Jess Savas, Phillip Williford, Laura Doerfler, Hafiz Shabbir Patwa, Joshua Waltonen, Christopher Sullivan, James Brown, Mercedes Porosnicu

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A132-A133; DOI: 10.1136/jitc-2020-SITC2020.0222
223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy
T Anders Olsen, Dylan Martini, Subir Goyal, Yuan Liu, Sean Evans, Benjamin Magod, Jacqueline Brown, Lauren Yantorni, Greta Russler, Sarah Caulfield, Jamie Goldman, Bassel Nazha, Wayne Harris, Viraj Master, Omer Kucuk, Bradley Carthon, Mehmet Bilen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A133; DOI: 10.1136/jitc-2020-SITC2020.0223
228 Radiological dynamics and resistance types in patients with advanced melanoma treated with anti-PD-1 monotherapy
Xue Bai, Michelle Kim, Gyulnara Kasumova, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Justine Cohen, Donald Lawrence, Christine Freedman, Riley Fadden, Krista Rubin, Tatyana Sharova, Dennie Frederick, Keith Flaherty, Ryan Sullivan, Jun Guo, Genevieve Boland

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A136-A137; DOI: 10.1136/jitc-2020-SITC2020.0228
240 Identification of lung cancer mutational signatures and tumor drivers associated with specific bimodal PD-L1/TMB status
Fernando Lopez-Diaz, Lauryn Keeler, Sally Agersborg, Lawrence Weiss, Vincent Funari

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A142-A143; DOI: 10.1136/jitc-2020-SITC2020.0240
239 Decr2 loss promotes resistance of tumor cells to immunotherapy by affecting CD8+ T cell-regulated tumor ferroptosis
Thomas Gajewski, Emily Higgs, Shuyin Li, Blake Flood, Ken Hatogai

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A142; DOI: 10.1136/jitc-2020-SITC2020.0239
242 Monitoring MDSC – a hurdle to immune checkpoints inhibitors
Damien Montamat-Sicotte, Laetitia Cortes, Virginia Litwin, Henry Hepburne-Scott, Phoebe Bonner

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A144; DOI: 10.1136/jitc-2020-SITC2020.0242

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages